Thinly traded BioNTech SE (NASDAQ:BNTX) jumps 55% premarket on light volume in reaction to its announcement that
it expects to initiate clinical testing of BNT162, its mRNA vaccine
candidate against COVID-19, by the latter part of next month (subject to
regulatory sign-off).
It plans to jointly develop the vaccine in China
with Fosun Pharma. It is advancing talks with collaboration partner
Pfizer (NYSE:PFE) for development ex-China.
It will manufacture BNT162 in Europe with partner Polymun.
https://seekingalpha.com/news/3551894-biontech-up-55-premarket-on-advancement-of-coronavirus-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.